7966 related articles for article (PubMed ID: 11599896)
1. The EORTC melanoma group translational research program on prognostic factors and ultrastaging in association with the adjuvant therapy trials in stage II and stage III melanoma. European Organization for Research and Treatment of Cancer.
Eggermont AM; Keilholz U; Testori A; Cook M; Lienard D; Ruiter DJ
Ann Surg Oncol; 2001 Oct; 8(9 Suppl):38S-40S. PubMed ID: 11599896
[TBL] [Abstract][Full Text] [Related]
2. Molecular staging of early colon cancer on the basis of sentinel node analysis: a multicenter phase II trial.
Bilchik AJ; Saha S; Wiese D; Stonecypher JA; Wood TF; Sostrin S; Turner RR; Wang HJ; Morton DL; Hoon DS
J Clin Oncol; 2001 Feb; 19(4):1128-36. PubMed ID: 11181678
[TBL] [Abstract][Full Text] [Related]
3. Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study).
Fusi A; Collette S; Busse A; Suciu S; Rietz A; Santinami M; Kruit WH; Testori A; Punt CJ; Dalgleish AG; Spatz A; Eggermont AM; Keilholz U
Eur J Cancer; 2009 Dec; 45(18):3189-97. PubMed ID: 19793643
[TBL] [Abstract][Full Text] [Related]
4. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991.
Eggermont AM; Suciu S; Testori A; Kruit WH; Marsden J; Punt CJ; Santinami M; Salès F; Schadendorf D; Patel P; Dummer R; Robert C; Keilholz U; Yver A; Spatz A
Eur J Cancer; 2012 Jan; 48(2):218-25. PubMed ID: 22056637
[TBL] [Abstract][Full Text] [Related]
5. The Sunbelt Melanoma Trial.
McMasters KM
Ann Surg Oncol; 2001 Oct; 8(9 Suppl):41S-43S. PubMed ID: 11599897
[TBL] [Abstract][Full Text] [Related]
6. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity.
Eggermont AM; Suciu S; Rutkowski P; Kruit WH; Punt CJ; Dummer R; Salès F; Keilholz U; de Schaetzen G; Testori A;
Eur J Cancer; 2016 Mar; 55():111-21. PubMed ID: 26790144
[TBL] [Abstract][Full Text] [Related]
7. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma.
Eggermont AM; Suciu S; Testori A; Santinami M; Kruit WH; Marsden J; Punt CJ; Salès F; Dummer R; Robert C; Schadendorf D; Patel PM; de Schaetzen G; Spatz A; Keilholz U
J Clin Oncol; 2012 Nov; 30(31):3810-8. PubMed ID: 23008300
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients.
Bostick PJ; Morton DL; Turner RR; Huynh KT; Wang HJ; Elashoff R; Essner R; Hoon DS
J Clin Oncol; 1999 Oct; 17(10):3238-44. PubMed ID: 10506625
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial.
Eggermont AMM; Rutkowski P; Dutriaux C; Hofman-Wellenhof R; Dziewulski P; Marples M; Grange F; Lok C; Pennachioli E; Robert C; van Akkooi ACJ; Bastholt L; Minisini A; Marshall E; Salès F; Grob JJ; Bechter O; Schadendorf D; Marreaud S; Kicinski M; Suciu S; Testori AAE
Eur J Cancer; 2020 Jul; 133():94-103. PubMed ID: 32470710
[TBL] [Abstract][Full Text] [Related]
10. Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991.
Bouwhuis MG; Suciu S; Testori A; Kruit WH; Salès F; Patel P; Punt CJ; Santinami M; Spatz A; Ten Hagen TL; Eggermont AM
J Clin Oncol; 2010 May; 28(14):2460-6. PubMed ID: 20385998
[TBL] [Abstract][Full Text] [Related]
11. Molecular Staging of Sentinel Lymph Nodes Identifies Melanoma Patients at Increased Risk of Nodal Recurrence.
Kimbrough CW; Egger ME; McMasters KM; Stromberg AJ; Martin RC; Philips P; Scoggins CR
J Am Coll Surg; 2016 Apr; 222(4):357-63. PubMed ID: 26875070
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of serial blood S100B determinations in stage IIB-III melanoma patients: a corollary study to EORTC trial 18952.
Bouwhuis MG; Suciu S; Kruit W; Salès F; Stoitchkov K; Patel P; Cocquyt V; Thomas J; Liénard D; Eggermont AM; Ghanem G;
Eur J Cancer; 2011 Feb; 47(3):361-8. PubMed ID: 21087856
[TBL] [Abstract][Full Text] [Related]
13. Melanoma patient staging: histopathological versus molecular evaluation of the sentinel node.
Davids V; Kidson SH; Hanekom GS
Melanoma Res; 2003 Jun; 13(3):313-24. PubMed ID: 12777989
[TBL] [Abstract][Full Text] [Related]
14. Surgical management of the groin lymph nodes in melanoma in the era of sentinel lymph node dissection.
Essner R; Scheri R; Kavanagh M; Torisu-Itakura H; Wanek LA; Morton DL
Arch Surg; 2006 Sep; 141(9):877-82; discussion 882-4. PubMed ID: 16983031
[TBL] [Abstract][Full Text] [Related]
15. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
Eggermont AM; Suciu S; MacKie R; Ruka W; Testori A; Kruit W; Punt CJ; Delauney M; Sales F; Groenewegen G; Ruiter DJ; Jagiello I; Stoitchkov K; Keilholz U; Lienard D;
Lancet; 2005 Oct; 366(9492):1189-96. PubMed ID: 16198768
[TBL] [Abstract][Full Text] [Related]
16. Low-dose adjuvant interferon for stage III malignant melanoma.
Inman JL; Russell GB; Savage P; Levine EA
Am Surg; 2003 Feb; 69(2):127-30. PubMed ID: 12641352
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study.
Grob JJ; Jouary T; Dréno B; Asselineau J; Gutzmer R; Hauschild A; Leccia MT; Landthaler M; Garbe C; Sassolas B; Herbst RA; Guillot B; Chene G; Pehamberger H
Eur J Cancer; 2013 Jan; 49(1):166-74. PubMed ID: 22975216
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial.
Eggermont AM; Suciu S; Rutkowski P; Marsden J; Santinami M; Corrie P; Aamdal S; Ascierto PA; Patel PM; Kruit WH; Bastholt L; Borgognoni L; Bernengo MG; Davidson N; Polders L; Praet M; Spatz A
J Clin Oncol; 2013 Oct; 31(30):3831-7. PubMed ID: 24019551
[TBL] [Abstract][Full Text] [Related]
19. Lessons learned from the Sunbelt Melanoma Trial.
McMasters KM; Noyes RD; Reintgen DS; Goydos JS; Beitsch PD; Davidson BS; Sussman JJ; Gershenwald JE; Ross MI;
J Surg Oncol; 2004 Jul; 86(4):212-23. PubMed ID: 15221928
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in the care of the patient with malignant melanoma.
Reintgen D; Balch CM; Kirkwood J; Ross M
Ann Surg; 1997 Jan; 225(1):1-14. PubMed ID: 8998115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
